Topotecan Episcleral Plaque for Treatment of Retinoblastoma

STATUS

Recruiting
End date

Oct 15, 2030
participants needed

30
sponsor

The Hospital for Sick Children

Send

Updated on 19 February 2024

See if I qualify

platelet count

renal function

topotecan

brachytherapy

intraocular retinoblastoma

Summary

This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active residual or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

Description

Retinoblastoma is the most common pediatric malignant intraocular tumour and originates from the retina. Treatment of eyes with advanced intraocular retinoblastoma remains a challenge. The historic standard of care for patients with unilateral disease is enucleation and for those with bilateral disease, a variety of modalities have been tried. These include radiation therapy, systemic chemotherapy, periocular administration of chemotherapy, selective intra-arterial chemotherapy, and intravitreal chemotherapy. Unfortunately, all of these modalities are associated with significant morbidity and investigators are looking for new ways to treat these patients either with novel directed drug delivery methods or with new less toxic agents. This study will evaluate the safety and efficacy of topotecan delivered directly to the eye using a novel sustained-release topotecan episcleral plaque (also referred to as a Chemoplaque) in patients with active residual or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy. The study intervention involves the insertion and removal of the Chemoplaque, examinations under anaesthesia (EUAs), visits to clinic to monitor for adverse events throughout, and post plaque removal toxicity evaluation. EUAs, clinic visits and laboratory tests are standard of care for retinoblastoma patients.

Details

Condition	Retinoblastoma, Retinoblastoma
Age	17 years and younger
Treatment	Topotecan Episcleral Plaque
Clinical Study Identifier	NCT04428879
Sponsor	The Hospital for Sick Children
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Age. Patients must be <18 years of age.'
	b'Diagnosis and Treatment. Patients must have active residual or recurrent intraocular'
	b'retinoblastoma in at least one eye following completion of first-line therapy'
	b'(chemotherapy, systemic or intra-arterial, or brachytherapy).'
	b'One eye will be the Study Eye. When patients have two eyes with retinoblastoma, the'
	b'eye with worst disease or best vision potential will be designated the Study Eye.'
	b'There will only be one eye per child treated in this Phase I study, since treatment of'
	b'two eyes would double the systemic dose of drug. The Non-study eye will be treated by'
	b'tandard of care, with only focal therapy during the Study Period, if required.'
	b'Disease status. Study eye must have vision potential and no clinical features'
	b'uggestive of high risk of extraocular extension.'
	b'Performance status. Lansky play score \\u2265 50 if <16 years of age; Karnofsky performance'
	b'cale of \\u2265 50 if \\u226516 years of age (Appendix I)'
	b'Organ function:'
	b'Adequate bone marrow function and platelet count'
	b'Adequate renal function'
	b'Adequate liver function'
	b'Pregnancy prevention. Females of reproductive potential must agree to the use of'
	b'highly effective contraception during study participation and for an additional 40'
	b'days after the end of the Chemoplaque administration'
	b'Informed consent. All patients and/or their parents or legally authorized'
	b'representatives must have the ability to understand and the willingness to sign a'
	b'written informed consent. Assent, where appropriate, will also be obtained.'
Exclusion Criteria
	b'Disease status. Any of the following:'
	b'tumour involving the optic nerve rim'
	b'clinical or EUA evidence of extraocular extension'
	b'evidence of metastatic retinoblastoma'
	b'existing neuroimaging showing suspicion of, or definitive, optic nerve invasion,'
	b'trilateral retinoblastoma or extra-ocular extension.'
	b'Allergy. Reported allergy to topotecan, camptothecin or derivatives thereof.'
	b'Concomitant treatment. Patients may not receive chemotherapy or other focal'
	b'retinoblastoma therapy or any other investigational agent within 3 weeks of the'
	b'placement and removal of the Chemoplaque, nor while the Chemoplaque is in situ.'
	b'Uncontrolled intercurrent illness. Patients with uncontrolled intercurrent illness'
	b"that, in the investigator's opinion, would put the participant at undue risk or limit"
	b'compliance with the study requirements.'
	b'Febrile illness. Patients with clinically significant febrile illness (as determined'
	b'by the investigator) within one week prior to initiation of protocol therapy.'
	b'Pregnancy and lactation. Females of reproductive potential must have a negative serum'
	b'pregnancy test within 72 hours prior to initiation of protocol therapy. Due to the'
	b'unknown but potential risk for adverse events (AEs) in nursing infants secondary to'
	b'treatment of the mother with the study agents, breastfeeding must be discontinued if'
	b'the mother is treated on study.'
	b'Compliance. Any condition of diagnosis that could in the opinion of the Principal'
	b"Investigator or delegate interfere with the participant's ability to comply with the"
	b'tudy instruction, might confound the interpretation of the study results, or put the'
	b'participant at risk.'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

intraocular retinoblastoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Topotecan Episcleral Plaque for Treatment of Retinoblastoma